Carefully consider the potential benefits and risks of TORADOL and other treatment options before deciding to use TORADOL. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of ketorolac tromethamine and TORADOLORAL is not to exceed 5 days. In adults, the use of TORADOLORAL is only indicated as continuation therapy to IV or IM dosing of ketorolac tromethamine.
Transition from IV or IM dosing of ketorolac tromethamine (single- or multiple-dose) to multiple-dose TORADOLORAL:
Patients age 17 to 64: 20 mg PO once followed by 10 mg q4-6 hours prn not >40 mg/day
Patients age ≥65, renally impaired, and/or weight<50 kg (110 lbs): 10 mg PO once followed by 10 mg q4-6 hours prn not >40 mg/day
Note:
Oral formulation should not be given as an initial dose
Use minimum effective dose for the individual patient
Do not shorten dosing interval of 4 to 6 hours
Total duration of treatment in adult patients: the combined duration of use of IV or IM dosing of ketorolac tromethamine and TORADOLORAL is not to exceed 5 days.
The following table summarizes TORADOLORAL dosing instructions in terms of age group:
Table 4 Summary of Dosing Instructions
| Patient Population |
TORADOLORAL
(following IV or IM dosing of ketorolac tromethamine) |
| Age <17 years |
Oral not approved |
| Adult Age 17 to 64 years |
20 mg once, then 10 mg q4-6 hours prn not >40 mg/day |
| Adult Age ≥65 years, renally impaired, and/or weight <50 kg |
10 mg once, then 10 mg q4-6 hours prn not >40 mg/day |
